JTH will no longer have an active presence on X. While this account will remain available as an archive, we will no longer post new content or monitor engagement. To continue receiving updates, follow us on: LinkedIn: bit.ly/3GMe8Lw BlueSky: bit.ly/4dizFHF

The Repeat Study addressed a really important knowledge gap! The incidence of recurrent events following an ante- or postpartum VTE is 2.4% person-years. The cumulative risks are 6%, 13%, 17%, and 30% at 2, 5, 10, and 30 years respectively. jthjournal.org/article/S1538…

🚨How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the @isth SSC Subcommittee on Control of Anticoagulation @JTHjournal 🙏 Great team work with @CukerMd @LanaCastellucci @thachil jthjournal.org/article/S1538…

📰How we treat severe inherited antithrombin deficiency: lessons from cases homozygous for the Budapest 3 variant👉 pubmed.ncbi.nlm.nih.gov/3993…, publicado en @JTHjournal

This study provides new insights into VWF regulation in complement-mediated diseases, opening avenues for targeted therapies in TMA and atypical HUS! ✅ W1183R-CFH enhances VWF cleavage by ADAMTS-13, potentially reducing large prothrombotic multimers ✅ Identifies strong binding interactions between CFH and VWF fragments, influencing VWF structural changes ✅ Biophysical and computational modeling demonstrated mechanically induced conformational shifts in the VWF-A2 domain, making it more susceptible to cleavage @DrXLongZheng jthjournal.org/article/S1538…

Preventing arterial #thromboembolism (ATE) in high-risk cancer patients should focus on modifiable CV risk factors. Kim et al.'s study explores the link between cancer, CV risk factors, and ATE. @JTHjournal. authors.elsevier.com/a/1kh7B…

🔍 What are the key design and feasibility challenges in pediatric DOAC trials, and how can future antithrombotic studies be improved to ensure robust and clinically meaningful results? This Study ✅ Identifies common feasibility barriers, such as sample size adjustments and mismatched clinical populations ✅ Highlights the need for adaptive trial designs to better reflect real-world pediatric VTE management ✅ Stresses the importance of clinically meaningful endpoints and early clinician involvement in trial design jthjournal.org/article/S1538…

🔍 How can we accurately measure FVIII activity in hemophilia A patients receiving efanesoctocog, particularly in those also on long-term emicizumab therapy? ✅ Efanesoctocog, an ultra-extended half-life FVIII, can now be accurately measured even with emicizumab present ✅ Standard chromogenic assays (CSA) overestimate FVIII—but specific calibration with bovine reagents provides precise results ✅ Low inter-lab variability ensures consistent and reliable testing across centers 🔗jthjournal.org/article/S1538…

In this meta-Analysis of 16 studies (2300 patients), ✅ Peak & trough concentrations of apixaban and rivaroxaban established 📉 ✅ Age & kidney function impact drug levels—highlighting the need for personalized dosing ✅ Findings align with known pharmacokinetic studies 🔗jthjournal.org/article/S1538…

A PAR4 genetic variant (rs2227376) reduces venous thromboembolism (VTE) risk by decreasing platelet activation & thrombin generation 🐁 Mice with the PAR4-P322L mutation had smaller venous clots & fewer procoagulant platelets 💡 Could targeting PAR4 signaling be a future anti-thrombotic strategy? 🔗jthjournal.org/article/S1538…

🤖 AI Meets Coagulation Genetics! 🧬 Machine learning (ML) is revolutionizing genetic variant interpretation for coagulation factor deficiencies, with increasing focus on hemophilia A & B. 🔍 Key Insights: ✅ AI tools like Hema-Class improve variant classification & genotype-phenotype predictions ✅ Expanding beyond missense mutations is the next frontier ✅ AI-driven genomic analysis could enhance precision medicine for bleeding disorders 🔗 jthjournal.org/article/S1538…

Interested in the fundamentals of key topics in #thrombosis and #hemoastasis? Don't miss the BRAND NEW Educational Review Series in @isth @JTHjournal Check it out 👇

Individuals with a new cancer diagnosis and no stroke history have an increased risk of ischemic stroke which varies according to site and stage. Future research is needed to identify individuals at highest risk who may benefit from preventative treatment @DebSiegal 🔗jthjournal.org/article/S1538…

🔴Venous thromboembolism and Duration of Anticoagulation ⤵️ #2025Review @JTHjournal 🔹Basics of diagnosis and treatment of venous thromboembolism 🔹Category of Major persistent risk factor, requiring long term anticoagulation. 🔹Learn more here: bit.ly/3EAaVNZ

Something we really needed! Comprehensive and understandable review which can be useful to all early career professionals. Thanks to @JTHjournal for this educational review series. Looking forward to the next one jthjournal.org/article/S1538…

💡 Could Roxadustat be the next big thing in ITP treatment?  🔬 Roxadustat, a HIF-1α stabilizer, shows promising therapeutic potential for ITP by enhancing megakaryocyte development & immune modulation! 📊 Key Findings: ✅ Reduced ITP risk (OR 0.79, P=0.01) ✅ No significant adverse effects ✅ Meta-analysis suggests protective effect 🔗jthjournal.org/article/S1538…

🦠 Gut microbiota & progesterone play a crucial role in bone marrow mesenchymal stem cell (BM-MSC) dysfunction in PITP. 🧬 Increased progesterone leads to BM-MSC senescence & apoptosis, impairing immune regulation. 🔗jthjournal.org/article/S1538…

How do structural changes in the A1 domain of von Willebrand factor (VWF) lead to type 2M von Willebrand disease? 🧬🔬 This study reveals that both misfolding and hyperstabilization of A1 disrupt platelet adhesion—offering new insights into VWF function! 🔗jthjournal.org/article/S1538…

A single amino acid replacement (D189A) switches thrombin specificity from trypsin-like to chymotrypsin-like. The observation establishes a new paradigm in the field of trypsin-like proteases. 🔗jthjournal.org/article/S1538…